NEW YORK, March 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 22nd Annual ROTH OC Growth Stock Conference, being held in Laguna Niguel, CA. Mr.

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (the "Company") (Nasdaq: KERX) announced today the appointment of Ron Bentsur as Chief Executive Officer of the Company.

VALLEY COTTAGE, N.Y., Aug. 14 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. today announced that Samuel H. Rudman, Esq., has been appointed to XTL's Board of Directors, effective as of August 13, 2008. Mr. Rudman, 40, is a named partner at a U.S.

VALLEY COTTAGE, New York, June 6 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today that it has completed the analysis of results from a Phase I clinical trial with XTL-2125 in patients with chronic Hepatitis C.

NEW YORK, March 29 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today the completion of the Phase I study with XTL-6865. The primary goal of this Phase I study was to evaluate safety and pharmacokinetic properties of XTL-6865 in patients with chronic hepatitis C.